We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Jun 21, 2018

MASCC/ISOO Annual Meeting on Supportive Care in Cancer

05 / USE OF BONE PROTECTION IN PATIENTS WITH PRIMARY INTRACRANIAL TUMOURS ON LONG TERM CORTICOSTEROIDS

;

Brennock, J.;

O' Leary, N.;

Hayden, C.

bone

bisphosphonate

corticosteroid

protection

fracture

Abstract

1

Views

1

Views

Abstract

Fullscreen

thumbnail

Keywords

bone

bisphosphonate

corticosteroid

protection

fracture

Abstract

Introduction: Long term use of corticosteroids (CS) can be associated with significant morbidity, including development of glucocorticoid-induced osteoporosis and fractures. There are currently no specific standards pertaining to the use of bone protection in patients on long term CS in palliative care. As a significant proportion of these patients are on CS for prolonged periods, this area should be explored further. Objectives To ascertain current use of bone protection in a palliative cohort of patients with primary intracranial tumours on long term CS treatment To identify patients in this cohort who would likely have benefitted from receiving bone protection Methods Standards used: American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. These recommend that patients on long term glucocorticoid treatment (dose ≥7.5mg prednisolone daily for ≥ three months) should be on bone protection therapy (bisphosphonate). Methodology: Retrospective audit using chart review of patients with primary intracranial tumours on initial referral to Palliative Care Team (PCT). Results 32 eligible patients identified. 37.5% on steroids on admission, had been on steroids for > three months on initial assessment and had >three months to live. 12.5% had > six months to live and were on steroids on first assessment, and 6.25% had been on >3 month course of steroids. Conclusions 62% of patients initially assessed by PCT should have been considered for bone protection prior to referral. 45% of patients were not suitable for consideration for bone protection. 55% which could have potentially been considered for bone protection by the PCT following initial assessment.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.